FDA Approves New Pancreatic Cancer Drug
9 articles from 7 countries
The U.S. Food and Drug Administration (FDA) has approved Rasonque, a new oral treatment for a specific type of pancreatic cancer. Developed by Revolution Medicines, the drug has shown in clinical trials to double survival rates for patients with metastatic pancreatic cancer.
New Pancreatic Cancer Drug Approved by FDA, Doubles Survival Time
- The U.S. Food and Drug Administration (FDA) has approved a new once-daily oral targeted drug for pancreatic cancer. - This approval provides a new formal treatment option for patients with advanced stages of the disease. - Clinical trials indicate the drug nearly doubles the median survival time for treated patients.
New pancreatic cancer drug 'Rasonque' approved by US FDA, doubling survival rates
- The U.S. FDA has approved 'Rasonque' (daratumumab), a new pancreatic cancer drug developed by Revolution Medicines. - The drug reportedly reduces the risk of death by 60% and nearly doubles survival…
FDA approves new drug for advanced pancreatic cancer
- The FDA has approved daraxonrasib, a new daily pill for advanced pancreatic cancer. - The drug, branded Rasonque, targets a mutated protein fueling tumor growth, previously considered "undruggable."…
FDA Approves New Pancreatic Cancer Drug
- The U.S. Food and Drug Administration (FDA) has approved a new treatment that slows pancreatic cancer. - This breakthrough targets a specific mutation that makes the cancer particularly deadly. - Re…
US FDA approves Rasonque, a promising new treatment for pancreatic cancer
- The US FDA has approved Rasonque, a new oral treatment for a specific type of pancreatic cancer. - Developed by Revolution Medicines, the drug has shown in clinical trials to double survival time co…
US Agency Approves Pancreatic Cancer Drug That Doubles Survival Time
- The US FDA has approved Rasonque, a new drug for treating pancreatic cancer. - Clinical trials showed the drug can double survival time for certain patients. - While not a cure, Rasonque offers a ne…
FDA Approves Revolutionary Pancreatic Cancer Drug That Doubles Survival Rate
- The FDA has approved Rasonque, a new daily pill for metastatic pancreatic cancer, which has shown in clinical trials to double the survival rate for advanced-stage patients. - The drug works by bloc…
New Drug Doubles Pancreatic Cancer Survival Rate, FDA Approves Novel Treatment Targeting RAS
- A new drug, Rasonque (daratumumab), has been approved by the US FDA, significantly improving pancreatic cancer treatment. - The drug has been shown to double the survival time for patients with meta…
US approves new pancreatic cancer pill that doubles survival rates
- The US FDA has approved Rasonque, a new daily pill for advanced pancreatic cancer that has shown to double patient survival rates in clinical trials. - The treatment targets RAS proteins, which are …
